IVIoannis Vasilikos

Ioannis Vasilikos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ioannis Vasilikos has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spatially restricted iron-metabolism-associated stress programs prime invasive mesenchymal glioblastoma states in human tissue-context models

    by Christophe Petry, Ambra-Stella Boecke, Aso Omer Mohammed, Nishita S Ghariwala, Vatsal D Jariwala, Mohammad Al Shhab, Oliver Buchholz, Ioannis Vasilikos, Julia M Nakagawa, Andreas Vlachos, et al.

    Background: Glioblastoma (GBM) recurrence is driven by invasive tumor cells that infiltrate surrounding brain tissue and evade surgical and therapeutic eradication. While dysregulated iron handling is a well-recognized feature of malignant cancers, its contribution to invasive GBM cell states in the physiological context of human cortical tissue remains poorly defined. Methods: We performed multiregional single-nucleus RNA sequencing of human GBM specimens encompassing tumor core, tumor periphery, and infiltrated cortex to map iron-associated transcriptional programs validated by spatial transcriptomics. Correlative analyses were combined with functional validation using patient-derived GBM cell lines and human organotypic cortical slice cultures exposed to noncytotoxic iron supplementation to model iron-rich tumor microenvironments. Results: Malignant cells from the tumor core exhibited coordinated upregulation of iron uptake and storage pathways alongside invasion-associated gene programs. At single-cell resolution, iron metabolism and invasion signatures were correlated, defining a core-enriched malignant subpopulation with mesenchymal-like transcriptional identity, stress-adaptive features, and angiogenic signaling that aggregate in specific spatial niches. Functionally, iron exposure altered migration in a cell-state-dependent manner and increased tumor growth and invasion in human cortical slice cultures. Increased VIM, MMP9, and HIF1A expression was consistent with activation of mesenchymal-like and stress-response programs, although mechanistic dependence was not tested. Conclusion: Iron-handling and invasion-associated programs co-occur in a core-enriched mesenchymal-like GBM state. In patient-derived cell and human cortical slice models, noncytotoxic particulate and soluble iron altered migration in a cell-state-dependent manner and increased tissue invasion. These findings support iron availability as a component of the microenvironment associated with invasive GBM phenotypes, while its necessity and underlying mechanism remain to be established.

  • Open Access

    Riboflavin-sensitized UVA collagen crosslinking produced a controllable, dose-dependent increase in the nanomechanical strength of ex vivo bovine dura mater

    by Ioannis Vasilikos, Sukesh Mysore Swamy, Ulrich G. Hofmann, Ulrich Hubbe, Roland Rölz, Angeliki Stathi, Katerina Wolk, Daniel Strahnen, Amir El Rahal, Mukesch J. Shah, et al.

    Background: Dural defects, either from trauma, tumor resection, surgical approaches, genetics, or spontaneously represent a significant clinical challenge in neurosurgery. Given the established efficacy of riboflavin-sensitized ultraviolet-A (UVA) photo-crosslinking in ophthalmology, this study investigated its feasibility and dose-response characteristics as a novel strategy to biochemically augment the mechanical integrity and strength of ex-vivo bovine dura mater. Methods: Forty bovine dura mater specimens were treated ex vivo using riboflavin concentrations of 2, 4, or 8 mM combined with UVA irradiation at 0.3 or 3 mW/cm 2 . PBS-treated specimens exposed to UVA served as controls. Atomic force microscopy nanoindentation was used to measure the local elastic modulus in matched regions before and after treatment, enabling paired assessment of treatment-induced mechanical changes while minimizing inter-sample variability. Post-treatment stiffness, fold-change from baseline, and riboflavin dose-response relationships were analyzed statistically. Results: Baseline elastic moduli were equivalent across all groups (mean approximately 52 kPa, p = 0.92). While UVA alone caused a modest approximately 2- to 3-fold stiffness increase, riboflavin-UVA treatment produced a dramatic, concentration-dependent effect. The highest treatment (8 mM RF, 3 mW/cm 2 UVA) increased the elastic modulus 150-fold, from approximately 53 kPa to approximately 8,000 kPa. Post-UV stiffness exhibited a strong linear relationship with riboflavin concentration (R 2 = 0.994), indicating a precisely titratable crosslinking effect. All treatment conditions were statistically distinguishable (p < 0.001). Conclusion: Riboflavin-sensitized UVA crosslinking substantially increases the nanomechanical strength of ex vivo bovine dura mater in a controllable, dose-dependent manner. These findings establish a proof of concept for biochemical reinforcement of dural tissue that might be used clinically. As a next step evaluation using human dura, macroscopic biomechanical testing, penetration-depth analysis, and safety assessment is warranted.

  • Open Access

    Riboflavin-sensitized UVA collagen crosslinking produced a controllable, dose-dependent increase in the nanomechanical strength of ex vivo bovine dura mater

    by Ioannis Vasilikos, Sukesh Mysore Swamy, Ulrich G. Hofmann, Ulrich Hubbe, Roland Rölz, Angeliki Stathi, Katerina Wolk, Daniel Strahnen, Amir El Rahal, Mukesch J. Shah, et al.

    Background: Dural defects, either from trauma, tumor resection, surgical approaches, genetics, or spontaneously represent a significant clinical challenge in neurosurgery. Given the established efficacy of riboflavin-sensitized ultraviolet-A (UVA) photo-crosslinking in ophthalmology, this study investigated its feasibility and dose-response characteristics as a novel strategy to biochemically augment the mechanical integrity and strength of ex-vivo bovine dura mater. Methods: Forty bovine dura mater specimens were treated ex vivo using riboflavin concentrations of 2, 4, or 8 mM combined with UVA irradiation at 0.3 or 3 mW/cm². PBS-treated specimens exposed to UVA served as controls. Atomic force microscopy nanoindentation was used to measure the local elastic modulus in matched regions before and after treatment, enabling paired assessment of treatment-induced mechanical changes while minimizing inter-sample variability. Post-treatment stiffness, fold-change from baseline, and riboflavin dose-response relationships were analyzed statistically. Results: Baseline elastic moduli were equivalent across all groups (mean approximately 52 kPa, p=0.92). While UVA alone caused a modest approximately 2- to 3-fold stiffness increase, riboflavin-UVA treatment produced a dramatic, concentration-dependent effect. The highest treatment (8 mM RF, 3 mW/cm² UVA) increased the elastic modulus 150-fold, from approximately 53 kPa to approximately 8,000 kPa. Post-UV stiffness exhibited a strong linear relationship with riboflavin concentration (R² = 0.994), indicating a precisely titratable crosslinking effect. All treatment conditions were statistically distinguishable (p < 0.001). Conclusion: Riboflavin-sensitized UVA crosslinking substantially increases the nanomechanical strength of ex vivo bovine dura mater in a controllable, dose-dependent manner. These findings establish a proof of concept for biochemical reinforcement of dural tissue that might be used clinically. As a next step evaluation using human dura, macroscopic biomechanical testing, penetration-depth analysis, and safety assessment is warranted.

  • Autologous platelet-rich fibrin as an alternative epidural patch for persistent post-dural puncture headache: A single-center observational study

    by Ioannis Vasilikos, Katerina Argiti, Kevin Joseph, Daniel Strahnen, Angeliki Stathi, Amir El Rahal, Florian Volz, Katharina Wolf, Mukesch Johannes Shah, Jürgen Beck, et al.

    Objectives: Epidural blood patch (EBP) is the current standard of care for postdural puncture headache (PDPH). However, when EBP fails to provide relief, patients may experience discomfort and functional impairments. This study reports the safety and efficacy of a novel approach that uses autologous platelet-rich fibrin (PRF) as an alternative epidural patch. Methods: Sixty-seven patients with persistent PDPH symptoms after conservative medical treatment were screened. Among them, 12 (18%) patients underwent multiple EBP (range: 1–6), which failed to resolve the PDPH symptoms. As an alternative method, an epidural PRF patch (EPP) was used, in which PRF was injected percutaneously epidurally under fluoroscopic guidance. Patient symptoms were collected perioperatively, and a follow-up period of up to 6 months was conducted. Results: The 12 patients included showed good tolerance for the EPP procedure, with injection volumes ranging from 15 to 39 ml. Compared to EBP, patients reported a significant reduction in injection-associated pain, as measured by the unidimensional numeric rating scale, with a mean reduction of 52.8% (p ≤ 0.05). The headache impact test scores (HIT-6) obtained before and 6 months after EPP revealed a statistically significant reduction in symptoms by a mean of 33.3% (p ≤ 0.05). Moreover, no adverse effects were observed during follow up. It is noteworthy that all patients experienced significant relief from PDPH-associated symptoms 6 months after the intervention. Conclusion: EPP may be a viable solution for patients with persistent PDPH symptoms. Notably, the discomfort experienced due to pain during the EPP procedure was markedly less than that experienced during the EBP procedure. The fact that clinical improvement was observed after 6 months is encouraging and lays the groundwork for additional clinical investigations.


  • Open Access

    Platelet rich fibrin and commercial sealants for dural closure in neurosurgery: An in vitro study

    by Katerina Argiti, Mukesch J. Shah, Kevin Joseph, Vidhya M. Ravi, Angeliki Stathi, Florian Volz, Amir El Rahal, Daniel Strahnen, Jürgen Grauvogel, Roland Rölz, et al.

    Background: Watertight closure of the dura mater is essential after neurosurgical interventions to avoid complications such meningitis, intracranial hypotension and surgical site infections. In addition to conventional suturing techniques, various biomaterials have been proposed as sealants to minimize the risk of leakage. We previously reported that patient derived platelet-rich fibrin (PRF), an autologous biomaterial, significantly improves watertight dural closure when applied as an onlay over a standard running suture. To demonstrate the efficacy of this method, we aimed to compare this orthobiological approach with other commercially available sealants. Methods: We utilized an in vitro testing device that allowed for the assessment of watertight dura mater closure via hydrostatic testing. On our testing phantom using freshly harvested bovine dura maters, a standardized 20-mm incision was closed using a running suture, and the leak pressure was measured initially without (primary leak pressure) and subsequently with on lay augmentation (secondary leak pressure) using either PRF, fibrinogen- and thrombin-coated collagen patch (TachoSil®), collagen matrix graft (DuraGen®), Polyethylenglykol (PEG) and polyethylene glycol ester and trilysine amine hydrogel solution (DuraSeal®), polyethylene glycol, protein-reactive polyethylene glycol monomer coated collagen matrix (Hemopatch®) or polyethylenimine component autospray sealant (Adherus®). Results: The outcomes demonstrate that the usage of a dural onlay in addition to the standard running suture exhibited a substantial improvement in leak pressure compared to the running suture alone. Specifically, the median leak pressure was improved by 3.5 times, where the combined approach was able to withstand 38 cm H2O, whereas the running suture alone had a median leak pressure of 11 cm H2O. Upon evaluating the performance of the sealants, we identified two categories of dural sealants: a medium performance group (30 ± 2 cm H2O) comprised of Adherus® (31 cm H2O), DuraGen® (31 cm H2O), and Hemopatch® (28 cm H2O), and a high-performance group composed of DuraSeal® (45.5 cm H2O), and TachoSil® (41 cm H2O). Patient-derived PRF was able to withstand a max pressure of 45 cm H2O, falling into the high-performance group. Of all the sealants tested in this study, the PRF based patch demonstrated the lowest variance in leak pressure among all the tested sealants. Conclusions: Autologous platelet-rich fibrin in a two-step procedure displayed enhanced augmentation and reinforced watertight closure of the dura mater, exhibiting a four-fold increase in leak pressure compared to standard running suture alone. Among other commonly utilized commercial sealants, it ranked second with demonstrated consistency in its performance.


  • Open Access

    Intraoperative classification of CNS lymphoma and glioblastoma by AI-based analysis of Stimulated Raman Histology (SRH)

    by Pierre Scheffler, Jakob Straehle, Amir El Rahal, Daniel Erny, Boris Mizaikoff, Ioannis Vasilikos, Marco Prinz, Volker A. Coenen, Julia Kühn, Florian Scherer, et al.


  • Open Access

    Platelet rich fibrin three-layer reconstruction of the sellar floor after endoscopic endonasal transsphenoidal approach: technical note and initial experience

    by Mukesch Johannes Shah, Katerina Argiti, Julia M. Nakagawa, Angeliki Stathi, Emilia Schönen, Daniel Strahnen, Kevin Joseph, Jakob Straehle, Nicolas Neidert, Jürgen Beck, et al.

    Background: Cerebrospinal fluid (CSF) leakage frequently complicates endoscopic endonasal transsphenoidal pituitary resections, despite the use of lumbar drains, nasoseptal flaps, or commercial dura sealants. Managing this complication often requires revision surgery and increases the risk of infection. Platelet-rich fibrin (PRF), an affordable autologous biomaterial derived from the patient's blood through short, angulated centrifugation, contains growth factors and leukocytes embedded in a fibrin matrix. PRF exhibits regenerative properties in various surgical disciplines. This study assesses a three-layer sellar reconstruction method employing solid membranous (s-PRF) and high-viscosity injectable (i-PRF) forms of PRF.Materials and methods: We present our initial experience on a series of 22 patients with pituitary macroadenomas. For all patients, an endoscopic transnasal transsphenoidal approach was selected. Following the resection of the pathology, sellar reconstruction was accomplished using a three-layer orthobiologic technique. A membranous s-PRF was utilized as an inlay inside the opened sellar floor, followed by a layer of injectable i-PRF finally covered with another s-PRF membrane over the top to the sellar corridor.Results: In all cases the implementation of the proposed three-layer PRF reconstruction strategy was feasible and safe. During the 12-month follow-up period there were no adverse effects reported associated with the PRF application. 77% (17/22) of the patients demonstrated intraoperatively a cerebrospinal fluid (CSF) leak (Esposito Grade 1–3). In total, the proposed PRF reconstruction effectively prevented postoperative CSF leaks in 95% of the patients and in 94% of those with an Esposito Grade 1–3. One of the two patients with intraoperative Esposito Grade 3 developed a CSF leak on the first postoperative day, which was successfully managed with a lumbar drain for 5 days.Conclusion: Sellar reconstruction after endoscopic endonasal transsphenoidal resection of pituitary adenomas with PRF is feasible and safe. The three layer PRF augmentation is a novel technique to prevent CSF-leakage.


  • A fully ingrowing implant for cranial reconstruction: Results in critical size defects in sheep using 3D-printed titanium scaffold

    by U. Hubbe, S. Beiser, S. Kuhn, T. Stark, A. Hoess, H. Cristina-Schmitz, I. Vasilikos, M.C. Metzger, R. Rothweiler


  • Double tubular minimally invasive spine surgery: a novel technique expands the surgical visual field during resection of intradural pathologies

    by Ulrich Hubbe, Jan-Helge Klingler, Roland Roelz, Christoph Scholz, Katerina Argiti, Panagiotis Fistouris, Jürgen Beck, Ioannis Vasilikos

    OBJECTIVE: A major challenge of a minimally invasive spinal approach (MIS) is maintaining freedom of maneuverability through small operative corridors. Unfortunately, during tubular resection of intradural pathologies, the durotomy and its accompanying tenting sutures offer a smaller operating window than the maximum surface of the tube’s base. The objective of this study was to evaluate if a novel double tubular technique could expand the surgical visual field during MIS resection of intradural pathologies. METHODS: A total of 25 MIS resections of intradural extramedullary pathologies were included. A posterior tubular interlaminar fenestration was performed in all surgeries. A durotomy covering the whole diameter of the tubular base was the standard in all cases. After placement of two tenting sutures on each side of the durotomy and application of tension, the resulting surface of the achieved dura fenestration was measured after optical analysis of the intraoperative video. In the next step, a second tube, 2 mm thinner than and the same length as the first, was inserted telescopically into the first tube, resulting an angulated fulcrum effect on the tenting sutures. RESULTS: Optical surface analysis of the dura fenestration before and after the second tubular insertion verified a significant widening of the visual field of 43.1% (mean 18.84 mm2, 95% CI 16.8–20.8, p value < 0.001). There were no ruptured tenting sutures through the increased tension. Postoperative MRIs verified complete resection of the pathologies. CONCLUSIONS: Inserting a second tube telescopically during posterior minimally invasive tubular spinal intradural surgery leads to an angulated fulcrum effect on the dura tenting sutures which consequently increases the surface of the dura fenestration and induces a meaningful widening of the visual field.


  • Open Access

    Correction to: Integrity of dural closure after autologous platelet rich fibrin augmentation: an in vitro study

    by I. Vasilikos, J. Beck, S. Ghanaati, J. Grauvogel, T. Nisyrios, K. Grapatsas, U. Hubbe